HPC
ALNY icon

HM Payson & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

HM Payson & Co’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-68
Closed -$27K – 1128
2025
Q4 		$27K Buy
+68
New +$30.1K ﹤0.01% 794
2025
Q1 		– Sell
-252
Closed -$59.3K – 1040
2024
Q4 		$59.3K Buy
+252
New +$66.3K ﹤0.01% 615
2022
Q1 		– Sell
-218
Closed -$37K – 1047
2021
Q4 		$37K Buy
+218
New +$40.5K ﹤0.01% 663
2021
Q2 		– Sell
-465
Closed -$66K – 1089
2021
Q1 		$66K Buy
465
+255
+121% +$38.4K ﹤0.01% 553
2020
Q4 		$27K Sell
210
-52
-20% -$6.94K ﹤0.01% 714
2020
Q3 		$38K Buy
+262
New +$37.2K ﹤0.01% 604

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HM Payson & Co's ALNY Position: Q1 2026 in Review

HM Payson & Co sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 68 shares — an estimated $27K sold.

HM Payson & Co first reported a position in ALNY in Q3 2020 and held it in 6 quarters. The position peaked at $66K in Q1 2021. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • HM Payson & Co reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • HM Payson & Co sold 68 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $27K.
  • HM Payson & Co first reported a position in Alnylam Pharmaceuticals in Q3 2020 and held it in 6 quarters.
  • HM Payson & Co's Alnylam Pharmaceuticals position peaked at $66K in Q1 2021.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on HM Payson & Co's 13F filing for Q1 2026, filed 13 Apr 2026.